Table 1

Presenting clinical characteristics of pediatric AMKL patients (n=153)

CharacteristicsCBFA2T3/GLIS2 (n = 24)NUP98/KDM5A (n = 14)KMT2A-r (n = 14)RBM15/MKL1 (n = 18)Monosomy 7 (n = 9)Other (n = 74)All (n = 153)
Median age, y (range) 1.5 (0.5-4.0) 1.9 (0.8-8.5) 1.9 (0.7-12.0) 0.7* (0.1-2.7) 1.5 (0.5-17.1) 1.6 (0.1-15.1) 1.6 (0.1-17.1) 
Median WBC count (range) 17.3 × 109/L (7.5-300.1) 14.0 × 109/L (5.8-188.0) 7.4 × 109/L (1.1-31.0) 13.8 × 109/L (5.6-32.7) 14.5 × 109/L (8.7-90.2) 14.4 × 109/L (1.1-378.5) 13.7 × 109/L (1.1-378.5) 
Male, % 25 43 71 33 22 51 46 
Origin        
 AIEOP, % 42 21 36 17 22 32 31 
 DCOG/BFM/SLH, % 17 50 36 28 33 29 29 
 COG, % 42 29 29 56 45 39 40 
HSCT 11 (46%) 4 (29%) 9 (64%) 9 (50%) 5 (56%) 30 (36%) 63 (41%) 
4-y pEFS, % 33 ± 10 36 ± 13 36 ± 13 59 ± 12 33 ± 16 62 ± 6 51 ± 4 
4-y pOS, % 38 ± 10 36 ± 13 36 ± 13 70 ± 11 33 ± 16 70 ± 5 56 ± 4 
4-y pCIR, % 42 ± 10 36 ± 14 50 ± 14 6 ± 6 33 ± 18 22 ± 5 29 ± 4 
CharacteristicsCBFA2T3/GLIS2 (n = 24)NUP98/KDM5A (n = 14)KMT2A-r (n = 14)RBM15/MKL1 (n = 18)Monosomy 7 (n = 9)Other (n = 74)All (n = 153)
Median age, y (range) 1.5 (0.5-4.0) 1.9 (0.8-8.5) 1.9 (0.7-12.0) 0.7* (0.1-2.7) 1.5 (0.5-17.1) 1.6 (0.1-15.1) 1.6 (0.1-17.1) 
Median WBC count (range) 17.3 × 109/L (7.5-300.1) 14.0 × 109/L (5.8-188.0) 7.4 × 109/L (1.1-31.0) 13.8 × 109/L (5.6-32.7) 14.5 × 109/L (8.7-90.2) 14.4 × 109/L (1.1-378.5) 13.7 × 109/L (1.1-378.5) 
Male, % 25 43 71 33 22 51 46 
Origin        
 AIEOP, % 42 21 36 17 22 32 31 
 DCOG/BFM/SLH, % 17 50 36 28 33 29 29 
 COG, % 42 29 29 56 45 39 40 
HSCT 11 (46%) 4 (29%) 9 (64%) 9 (50%) 5 (56%) 30 (36%) 63 (41%) 
4-y pEFS, % 33 ± 10 36 ± 13 36 ± 13 59 ± 12 33 ± 16 62 ± 6 51 ± 4 
4-y pOS, % 38 ± 10 36 ± 13 36 ± 13 70 ± 11 33 ± 16 70 ± 5 56 ± 4 
4-y pCIR, % 42 ± 10 36 ± 14 50 ± 14 6 ± 6 33 ± 18 22 ± 5 29 ± 4 

KMT2A-r, KMT2A rearrangement.

*

Significantly lower age at diagnosis (P = .038).

View Large